Search results
Results from the WOW.Com Content Network
M9871/3 Acute myeloid leukemia with abnormal marrow eosinophils (includes all variants) AML with inv(16)(p13q22) or t(16;16)(p13;q22), CBFb/MYH11 (FAB M4Eo) M9872/3 Acute myeloid leukemia, minimally differentiated (FAB type M0) Acute myeloblastic leukemia] M9873/3 Acute myeloid leukemia, without maturation (FAB type M1)
Acute monocytic leukemia (AMoL, or AML-M5) [2] is a type of acute myeloid leukemia. In AML-M5 >80% of the leukemic cells are of monocytic lineage. [3] This cancer is characterized by a dominance of monocytes in the bone marrow. There is an overproduction of monocytes that the body does not need in the periphery.
AMML can be treated depending on the degree of disease, age of patient, and current patient's health status. Treatment consists of a multi-drug chemotherapy regimen. [11] Chemotherapy drugs often used to treat AML are cytarabine and an anthracycline drug. Chemotherapy is broken down into 2 phases:
The ICD-10 Procedure Coding System (ICD-10-PCS) is a US system of medical classification used for procedural coding.The Centers for Medicare and Medicaid Services, the agency responsible for maintaining the inpatient procedure code set in the U.S., contracted with 3M Health Information Systems in 1995 to design and then develop a procedure classification system to replace Volume 3 of ICD-9-CM.
Under the proposal, the ICD-9-CM code sets would be replaced with the ICD-10-CM code sets, effective October 1, 2013. On April 17, 2012, the Department of Health and Human Services (HHS) published a proposed rule that would delay the compliance date for the ICD-10-CM and PCS by 12 months-from October 1, 2013, to October 1, 2014. [4]
Acute megakaryoblastic leukemia (AMKL) is life-threatening leukemia in which malignant megakaryoblasts proliferate abnormally and injure various tissues. Megakaryoblasts are the most immature precursor cells in a platelet-forming lineage; they mature to promegakaryocytes and, ultimately, megakaryocytes which cells shed membrane-enclosed particles, i.e. platelets, into the circulation.
FLAG is a chemotherapy regimen used for relapsed and refractory acute myeloid leukemia (AML). [1] The acronym incorporates the three primary ingredients of the regimen: . Fludarabine: an antimetabolite that, while not active toward AML, increases formation of an active cytarabine metabolite, ara-CTP, in AML cells;
Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. [1] Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. [1]